Overview

The Impact of Proton Pump Inhibitors on the Fecal Microbiome

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons with an initial episode of clostridium difficile infection (CDI).
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Omeprazole
Proton Pump Inhibitors